Neurotech’s upgraded autism device gets Italcert approval

|

Published 04-JUN-2018 15:03 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Neurotech International Limited (ASX:NTI) — developer of quality medical solutions improving the lives of children with autism — has today announced that Italcert, its independent regulator for CE compliance, has approved considerable improvements to the Mente Autism device.

With this approval, the company is now in the position to move ahead with production of the next batch of Mente Autism devices, which is expected to occur this month before releasing the product to market in Europe.

Design improvements to the next iteration of the Mente Autism device, foreshadowed in NTI’s March quarterly update, include improvements to wi-fi connectivity, synchronisation and usability linked to the firmware and the Mente Autism application.

The CE mark shows that the Mente Device complies with European health, safety and environmental protection legislation. Given this latest development, production of the next batch of the device is now underway.

CEO of Neurotech International, Wolfgang Storf said: “This is another important milestone for the company. Over the past year, we have listened to feedback from our customers and distribution partners and many of the improvements we have introduced resulted from this feedback. Our distributors are looking forward to receiving the updated device, which is expected to be available in July.”

It should be noted though that market penetration is speculative despite the updates and any investment decision in this stock should be made with caution and professional financial advice sought.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder.

Designed for home use, the device helps relax the minds of children on the spectrum, which in turn helps them to focus better and engage positively with their environment.

As shown, the Mente Device is worn over the child’s ears. Source: www.mentetech.com


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X